Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Non-Current Debt (2024)

Universe Pharmaceuticals' Non-Current Debt history spans 1 years, with the latest figure at $2.1 billion for Q3 2024.

  • On a quarterly basis, Non-Current Debt changed N/A to $2.1 billion in Q3 2024 year-over-year; TTM through Sep 2024 was $2.1 billion, a N/A change, with the full-year FY2024 number at $2.1 billion, changed N/A from a year prior.
  • Non-Current Debt hit $2.1 billion in Q3 2024 for Universe Pharmaceuticals, up from $2.1 million in the prior quarter.
  • Over the last five years, Non-Current Debt for UPC hit a ceiling of $2.1 billion in Q3 2024 and a floor of $2.1 million in Q1 2024.